mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia.
Adult
Caudate Nucleus
/ diagnostic imaging
Chronic Disease
Cognitive Dysfunction
/ etiology
Humans
Male
Middle Aged
Neuropsychological Tests
Oximes
/ pharmacokinetics
Positron-Emission Tomography
Pyridines
/ pharmacokinetics
Receptor, Metabotropic Glutamate 5
/ metabolism
Schizophrenia
/ complications
Smoking
/ metabolism
Temporal Lobe
/ diagnostic imaging
chronic schizophrenia
cognition
mGluR5 receptor
negative symptoms
positron emission tomography
Journal
Human brain mapping
ISSN: 1097-0193
Titre abrégé: Hum Brain Mapp
Pays: United States
ID NLM: 9419065
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
21
10
2019
revised:
25
02
2020
accepted:
25
02
2020
pubmed:
10
3
2020
medline:
9
11
2021
entrez:
10
3
2020
Statut:
ppublish
Résumé
Consistent findings postulate disturbed glutamatergic function (more specifically a hypofunction of the ionotropic NMDA receptors) as an important pathophysiologic mechanism in schizophrenia. However, the role of the metabotropic glutamatergic receptors type 5 (mGluR5) in this disease remains unclear. In this study, we investigated their significance (using [
Identifiants
pubmed: 32150317
doi: 10.1002/hbm.24976
pmc: PMC7294054
doi:
Substances chimiques
GRM5 protein, human
0
Oximes
0
Pyridines
0
Receptor, Metabotropic Glutamate 5
0
fluoroethyl-desmethyl-ABP688
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2762-2781Informations de copyright
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals, Inc.
Références
Nat Neurosci. 2015 Feb;18(2):199-209
pubmed: 25599223
Nucl Med Biol. 2003 Nov;30(8):869-78
pubmed: 14698791
Psychopharmacology (Berl). 2010 May;209(4):343-50
pubmed: 20217053
J Sleep Res. 2016 Dec;25(6):754-761
pubmed: 27357735
Aust N Z J Psychiatry. 2009 Mar;43(3):277-82
pubmed: 19221917
Phys Med Biol. 2008 Jun 21;53(12):3217-30
pubmed: 18506070
Neuropsychopharmacology. 2001 Oct;25(4):505-13
pubmed: 11557164
Psychiatr Danub. 2009 Sep;21(3):371-5
pubmed: 19794359
Psychiatry Res. 2005 Nov 15;137(1-2):137-41
pubmed: 16225931
Schizophr Bull. 2007 May;33(3):688-702
pubmed: 17440198
Ann Gen Psychiatry. 2010 May 07;9:20
pubmed: 20459646
Ann N Y Acad Sci. 2012 Feb;1248:89-106
pubmed: 22129082
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9
pubmed: 9754841
Transl Psychiatry. 2013 Jun 18;3:e271
pubmed: 23778581
Psychiatry Res. 2016 Dec 30;246:1-8
pubmed: 27639816
Mol Psychiatry. 2006 Feb;11(2):118-9
pubmed: 16189506
J Int Neuropsychol Soc. 2009 May;15(3):438-50
pubmed: 19402930
Synapse. 2018 Sep;72(9):e22041
pubmed: 29935121
J Cereb Blood Flow Metab. 2011 Nov;31(11):2169-80
pubmed: 21792244
Br J Psychol. 2004 Feb;95(Pt 1):57-79
pubmed: 15005868
Neuropsychopharmacology. 2004 Aug;29(8):1522-6
pubmed: 15100704
Neuropharmacology. 2005 Jul;49(1):73-85
pubmed: 15992582
Mol Psychiatry. 2014 May;19(5):625-32
pubmed: 23628984
Nuklearmedizin. 2011;50(2):74-82
pubmed: 21286660
J Physiol. 2008 Mar 15;586(6):1481-6
pubmed: 18187472
Trends Neurosci. 2014 Feb;37(2):85-94
pubmed: 24388426
Schizophr Bull. 2017 May 1;43(3):601-610
pubmed: 27559077
Community Ment Health J. 1997 Feb;33(1):35-41
pubmed: 9061261
J Nucl Med. 2007 Feb;48(2):247-52
pubmed: 17268022
Arch Gen Psychiatry. 1989 Dec;46(12):1145-50
pubmed: 2589928
J Cereb Blood Flow Metab. 2017 Aug;37(8):2716-2727
pubmed: 27742888
Schizophr Res. 2017 May;183:95-101
pubmed: 27847228
Neuropsychopharmacology. 2012 Jan;37(1):4-15
pubmed: 21956446
Future Med Chem. 2013 Sep;5(13):1471-4
pubmed: 24024939
Annu Rev Pharmacol Toxicol. 2010;50:295-322
pubmed: 20055706
Arch Gen Psychiatry. 1982 Jul;39(7):784-8
pubmed: 7165477
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):737-42
pubmed: 23248277
Schizophr Res. 2011 May;128(1-3):7-14
pubmed: 21353485
Brain Cogn. 1998 Dec;38(3):317-38
pubmed: 9841789
Schizophr Bull. 2015 Nov;41(6):1397-402
pubmed: 25841041
J Neurosci. 1997 Jul 1;17(13):5196-205
pubmed: 9185557
Schizophr Res. 2017 Dec;190:172-179
pubmed: 28433500
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Biol Psychiatry. 2015 Feb 1;77(3):266-275
pubmed: 25156701
Neuropsychopharmacology. 2004 Jul;29(7):1259-69
pubmed: 15010696
J Clin Exp Neuropsychol. 2004 Oct;26(7):981-94
pubmed: 15742547
Synapse. 2005 Sep 1;57(3):123-31
pubmed: 15945063
Brain Res Mol Brain Res. 1998 May;56(1-2):207-17
pubmed: 9602129
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1179-1183
pubmed: 30627817
Eur Neuropsychopharmacol. 2005 Oct;15(5):557-61
pubmed: 16139173
Neuropharmacology. 2017 Mar 15;115:73-91
pubmed: 26349010
J Psychopharmacol. 2013 Apr;27(4):374-85
pubmed: 23118022
EJNMMI Phys. 2014 Jul;1(Suppl 1):A47
pubmed: 26501635
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Eur Neuropsychopharmacol. 2019 Dec;29(2):278-290
pubmed: 30553696
Am J Psychiatry. 2010 Dec;167(12):1489-98
pubmed: 20889653
Drug Alcohol Depend. 2015 Oct 1;155:202-7
pubmed: 26233484
Mol Psychiatry. 2018 Apr;23(4):824-832
pubmed: 28397841
Eur Psychiatry. 2013 Aug;28(6):332-9
pubmed: 22999439
Neuroimage. 2008 Aug 15;42(2):1032-44
pubmed: 18602840
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Ther Adv Psychopharmacol. 2019 Jul 01;9:2045125319859969
pubmed: 31308936
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Biol Psychiatry. 2010 Feb 1;67(3):255-62
pubmed: 19897178
Neuroimage. 2005 Oct 15;28(1):216-26
pubmed: 15979345
J Psychiatry Neurosci. 2017 Jun;42(4):273-283
pubmed: 28556775
Neurology. 2003 Dec 9;61(11 Suppl 6):S19-23
pubmed: 14663004
Schizophr Res. 2018 Feb;192:269-273
pubmed: 28412088
Front Psychiatry. 2018 Dec 06;9:672
pubmed: 30574101
Arch Gen Psychiatry. 2002 Aug;59(8):686-94
pubmed: 12150644
Arch Gen Psychiatry. 1997 Feb;54(2):159-65
pubmed: 9040284
Psychopharmacology (Berl). 2004 Sep;175(3):310-8
pubmed: 15024550
Nucl Med Biol. 2010 Oct;37(7):845-51
pubmed: 20870160
Am J Psychiatry. 2011 Jul;168(7):727-34
pubmed: 21498461
J Neurochem. 2009 Jun;109(5):1497-507
pubmed: 19344374
Mol Psychiatry. 2020 Apr;25(4):750-760
pubmed: 30214040
Curr Drug Targets. 2016;17(5):538-616
pubmed: 25777273
Mol Psychiatry. 2015 Oct;20(10):1151-60
pubmed: 26077694
Mol Brain. 2017 Apr 26;10(1):15
pubmed: 28446243
BMC Psychiatry. 2014 Jan 28;14:23
pubmed: 24472577
Int J Neuropsychopharmacol. 2014 Dec;17(12):1915-22
pubmed: 24833114
Schizophr Res. 2013 May;146(1-3):170-6
pubmed: 23462049
Psychopharmacology (Berl). 2008 May;198(1):141-8
pubmed: 18311557
Schizophr Res. 2005 Jul 15;76(2-3):135-57
pubmed: 15949648
Br J Pharmacol. 2017 Oct;174(19):3136-3160
pubmed: 28626937
Appl Neuropsychol. 2002;9(2):106-9
pubmed: 12214820
J Psychiatry Neurosci. 2014 Nov;39(6):407-16
pubmed: 24949866
Neuroscience. 2006 Oct 27;142(3):691-702
pubmed: 16890368
Isr J Psychiatry Relat Sci. 2010;47(1):4-16
pubmed: 20686195
Ann Gen Psychiatry. 2011 Jan 20;10:2
pubmed: 21251305
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Gene. 2013 Feb 15;515(1):163-6
pubmed: 23149219
Hum Brain Mapp. 2020 Jul;41(10):2762-2781
pubmed: 32150317
Trends Pharmacol Sci. 2009 Jan;30(1):25-31
pubmed: 19058862
J Am Geriatr Soc. 2010 Apr;58(4):719-23
pubmed: 20398153
Acta Psychiatr Scand. 2013 Oct;128(4):261-70
pubmed: 23216145
Transl Psychiatry. 2018 Jan 10;8(1):17
pubmed: 29317611
Biol Psychiatry. 2016 Mar 15;79(6):474-80
pubmed: 25861697
Curr Pharm Biotechnol. 2012 Jun;13(8):1500-12
pubmed: 22283750
Front Cell Neurosci. 2017 Feb 21;11:37
pubmed: 28270751
Br J Psychiatry Suppl. 2007 Dec;51:s107-10
pubmed: 18055925
J Pharmacol Exp Ther. 2003 Jul;306(1):116-23
pubmed: 12660307